Boxer Capital, LLC - 06 Feb 2024 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Other*
Signature
By: /s/ Aaron I. Davis, Chief Executive Officer, Boxer Capital, LLC
Issuer symbol
TYRA
Transactions as of
06 Feb 2024
Net transactions value
+$9,999,978
Form type
4
Filing time
08 Feb 2024, 17:09:52 UTC
Previous filing
25 Jan 2024
Next filing
14 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Award $824,990 +63,412 +281% $13.01 85,939 06 Feb 2024 See Footnote F1
holding TYRA Common Stock 6,448,359 06 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Warrant (right to purchase) Award $9,174,988 +705,280 $13.01 705,280 06 Feb 2024 Common Stock 705,280 $0.001000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F2 These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
F3 These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date.

Remarks:

The reporting persons may be deemed members of a group that beneficially owns more than 10% of the outstanding shares of the outstanding shares of Tyra Biosciences, Inc. common stock ("Common Stock"), par value $0.0001 per share